Results 11 to 20 of about 677,503 (281)

Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy [PDF]

Molecules, 2020
Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five subtypes described. The interaction between SST and its receptors leads
Romain Eychenne, Mickael Bourgeois, Pascal Loyer   +2 more
exaly   +5 more sources

²²⁵Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic [PDF]

Pharmaceutics, 2023
The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu-radiolabeled somatostatin analogs. These radiopharmaceuticals have especially
Léa Rubira, Emmanuel Deshayes, Lore Santoro, Pierre Olivier Kotzki, Cyril Fersing   +4 more
doaj   +3 more sources

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World

Frontiers in Endocrinology, 2021
Neuroendocrine tumors overexpress somatostatin receptors, which serve as important and unique therapeutic targets for well-differentiated advanced disease.
Mayank Patel, Isabel Tena, Isabel Tena, Abhishek Jha, David Taieb, Karel Pacak   +5 more
doaj   +2 more sources

Somatostatin analogs: Clinical application in relation to human somatostatin receptor subtypes [PDF]

Biochemical Pharmacology, 1995
Radiolabeled octreotide analogs are most successfully being applied today in clinical cancer imaging and treatment. Propagation of this paradigm to other radiopeptide families has been greatly hampered by the inherent poor metabolic stability of ...
Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven), Visser-Wisselaar, H.A. (Heleen)   +2 more
core   +18 more sources

Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors

BMC Cancer, 2019
Background Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs.
Florian Bösch, Alexandr V. Bazhin, Sabine Heublein, Katharina Brüwer, Thomas Knösel, Florian P. Reiter, Christoph J. Auernhammer, Markus O. Guba, Christine Spitzweg, Jens Werner, Martin K. Angele   +10 more
doaj   +2 more sources

18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study

EJNMMI Research, 2018
Background Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, 18F-fluoro-deoxy-glucose (18F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of 68Ga-somatostatin analogs.
Silvia Taralli, Martina Sollini, Michele Milella, Germano Perotti, Angelina Filice, Massimo Menga, Annibale Versari, Vittoria Rufini   +7 more
doaj   +2 more sources

A case of malignant insulinoma responsive to somatostatin analogs treatment [PDF]

BMC Endocrine Disorders, 2018
Background Insulinoma is a rare tumour representing 1–2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), CK19 status, the tumor staging and ...
Mariasmeralda Caliri, Valentina Verdiani, Edoardo Mannucci, Vittorio Briganti, Luca Landoni, Alessandro Esposito, Giulia Burato, Carlo Maria Rotella, Massimo Mannelli, Alessandro Peri   +9 more
doaj   +2 more sources

Somatostatin analogs: Future directions [PDF]

Metabolism, 1996
Herder, W.W. (Wouter) de, Hofland, L.J. (Leo), Lamberts, S.W.J. (Steven), Lely, A-J. (Aart-Jan) van der   +3 more
core   +4 more sources

Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. [PDF]

Cancers (Basel), 2022
Simple Summary Somatostatin receptors (SSTs) are of particular interest in oncology because these proteins are overexpressed on the cell membranes of different human malignancies, especially neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs)
Fani M, Mansi R, Nicolas GP, Wild D.
europepmc   +2 more sources

Somatostatin analog therapy in delaying progression of polycystic liver disease: A meta-analysis with trial sequential analysis [PDF]

iLIVER
Background and aims: Polycystic liver disease (PLD) can occur independently or in association with autosomal dominant polycystic kidney disease and has no effective medical therapy.
Mohammed S. Beshr, Rana H. Shembesh, Bisher Sawaf, Shahem Abbarh, Mohammed Abu-Rumaileh, Monica Tincopa, Muhammed Elhadi   +6 more
doaj   +2 more sources